The path to successful clinical development of oncology drugs starts with using predictive tumor models. This is easier said than done.
The organizers of the Tumor Models meeting in London (January 29-31, 2013) have assembled a roster of speakers from AstraZeneca, Eisai, Roche, MedImmune, Genentech, Sanofi and others to discuss tumor models used at these companies, optimization of traditional models, and explore alternative models and methods to better predict drug efficacy.
Oncology targets, strategies, cancer drug development and personalized medicine
